About the Authors

Sylvain Rheims, Philippe Ryvlin
Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Lyon, France

Sylvain Rheims, Alexis Arzimanoglou, Philippe Ryvlin
CTRS INSERM-IDEE, Institute for Children and Adolescents with Epilepsy, Hospices Civils de Lyon, Lyon, France

Michel Cucherat
Department of Clinical Pharmacology, EA 643, Lyon-1 University, Laennec Faculty of Medicine, Lyon, France

Alexis Arzimanoglou
Department of Epileptology, Sleep and Pediatric Neurophysiology, Hospices Civils de Lyon, Lyon, France

Philippe Ryvlin
INSERM U821, Lyon, France

Corresponding Author

ryvlin@cermep.fr

Competing Interests

SR has received speaker fees from Pfizer. MC has no conflict of interest. AA has received speaker or consultant fees from Pfizer, Sanofi-Aventis, GlaxoSmithKline (GSK), Jansen-Cilag, UCB Pharma, EISAI, and Valeant. PR has received speaker fees from Cyberonics, Eisai, GSK, Janssen-Cilag, Novartis, Pfizer, Sanofi-Synthelabo, and UCB; and consultant fees from Cyberonics, GSK, Janssen-Cilag, Novartis, Pfizer, UCB, and Valeant.